Labcorp Opens New Integrated Laboratory, Strengthens Bioanalytical Services in Asia-Pacific
PR93116
SINGAPORE, Nov. 29, 2021 /PRNewswire=KYODO JBN/ --
- Expanded Facility Provides Comprehensive Capabilities to Support Global
Pharmaceutical Drug Development Programs
Labcorp (http://www.labcorp.com/)(NYSE: LH), a leading global life sciences
company, today announced the expansion of its global offerings and its
footprint in the Asia-Pacific (APAC) region with the opening of a new,
integrated bioanalytical laboratory in Singapore.
The laboratory features new capabilities that enhance the substantial array of
bioanalytical services currently offered through Labcorp Drug Development
(http://www.drugdevelopment.labcorp.com/), allowing the company to meet
increased demand from pharmaceutical and biotechnology companies.
"Singapore serves as a strategic location from which Labcorp can increase
accessibility by offering regional and international clients comprehensive
support for their bioanalytical studies," said Dr. Paul Kirchgraber, CEO of
Labcorp Drug Development. "With this expansion, the company is advancing its
position as a life science leader in the region and across the globe. The
all-in-one Singapore laboratory offers clients faster turnaround times for data
in early phase trials occurring in the APAC region."
The integrated bioanalytical laboratory will be co-located with Labcorp's
Central Laboratory Services and Clinical Development and Commercialization
Services segments, bolstering the company's laboratory network in APAC. By
expanding its bioanalytical capabilities in Singapore, Labcorp advances its
regulated and non-regulated services and further supports the development of
small and large molecule studies. The new, integrated laboratory will also
offer Good Laboratory Practice (GLP)- and Good Clinical Practice
(GCP)-compliant bioanalysis, liquid chromatography-mass spectrometry and
immunochemistry platforms, as well as clinical biomarker analytical services.
Labcorp hosted an opening ceremony for the laboratory on Wednesday, Nov. 10.
Gan Kim Yong, Singapore's minister for trade and industry, and Dr. Kirchgraber
officiated the opening ceremony. The event also featured a keynote
presentation, a virtual lab tour and scientific sessions from an impressive
line-up of Labcorp Drug Development scientists.
In line with Singapore's plans for Emerging Stronger, this expansion will
strengthen the nation's position as an end-to-end hub for medical technology
product development under the Alliance for Action approach. It will also enable
comprehensive, end-to-end in vitro diagnostic solutions development and
commercialization.
About Labcorp
Labcorp is a leading global life sciences company that provides vital
information to help doctors, hospitals, pharmaceutical companies, researchers,
and patients make clear and confident decisions. Through our unparalleled
diagnostics and drug development capabilities, we provide insights and
accelerate innovations to improve health and improve lives. With more than
70,000 employees, we serve clients in more than 100 countries. Labcorp (NYSE:
LH) reported revenue of $14 billion in FY2020. Learn about Labcorp at
www.labcorp.com, or follow us on LinkedIn
(https://www.linkedin.com/company/labcorp) and Twitter @Labcorp
(https://twitter.com/LabCorp).
SOURCE: Labcorp Drug Development
Image Attachments Links:
Link: http://asianetnews.net/view-attachment?attach-id=407884
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。